egfrt/19-28z/4-1bbl car t cells
Cell therapyexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Feb 27, 2017 (NCT03070327)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Epidermal growth factor receptor erbB1Immunity, passive
EGFR immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- egfrt/19-28z/4-1bbl car t cells
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06343376 | Phase 1 | Nov 15, 2024 | State University of New York, Buffalo |
| NCT03085173 | Phase 1 | Mar 15, 2017 | Cornell University, Juno Therapeutics, Inc. |
| NCT03070327 | Phase 1 | Feb 27, 2017 | Cornell University, Juno Therapeutics, Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cornell University | Academic/Hospital | 2 | 2 | 1 | 2017 |
| Juno Therapeutics, Inc. | For profit | 2 | 0 | 1 | 2017 |
| State University of New York, Buffalo | Academic/Hospital | 1 | 1 | 1 | 2024 |
3 organizations
Page 1 / 1